LHVS

LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC50 of 10 μM[1][2][3].

Product Specifications

CAS Number

170111-28-1

UNSPSC

12352005

Target

Cathepsin; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lhvs.html

Purity

98.03

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCOCC1)N[C@H](C(N[C@@H](CCC2=CC=CC=C2)/C=C/S(=O)(C3=CC=CC=C3)=O)=O)CC(C)C

Molecular Formula

C28H37N3O5S

Molecular Weight

527.68

References & Citations

[1]Wilson SR, et al. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem. 2009 Jan 23;284 (4) :2584-92.|[2]Teo CF, et al.Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. Antimicrob Agents Chemother. 2007 Feb;51 (2) :679-88.|[3]Riese RJ, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996 Apr;4 (4) :357-66.|[4]Barclay J, et al. Role of the cysteine protease cathepsin S in neuropathic hyperalgesia. Pain. 2007 Aug;130 (3) :225-234.|[5]Clark AK, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007 Jun 19;104 (25) :10655-60.